Ziopharm Oncology (ZIOP -3.4%) slips on a downgrade to Hold at Jefferies morning. The firm also cut its price target on the stock to $4 from $7 a share, citing increased clinical risks after the firm met with oncology experts to discuss ZIOP's palifosfamide. The discussions indicate a sub-50% probability the drug will meet its OS endpoint, which is necessary for FDA approval.
Ziopharm Oncology (ZIOP -3.4%) slips on a downgrade to Hold at Jefferies morning. The firm also...
From other sites
Video at CNBC.com (May 18, 2016)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Feb 14, 2013)
at CNBC.com (Jul 20, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs